ABSTRACT: Wear particle-induced osteolysis is a major cause of aseptic loosening, which is one of the most common reasons for total hip arthroplasty (THA) failure. Previous studies have shown that the expression of Receptor activation of nuclear factor (NF)-kB (RANKL) by fibroblasts in periprosthetic membrane played a crucial role in wear particle-induced osteolysis. However, the underlying mechanism of RANKL expression remains largely unknown. In the present study, we investigated the effect of TiAl 6 V 4 particle (TiPs)-induced XBP1s (spliced form of X-box binding protein 1) on RANKL expression and osteoclastogenesis both in vitro and in vivo. The levels of XBP1s in peri-implant membrane, animal models, and TiPs-stimulated fibroblasts were determined by western blots. To assess the effect of XBP1s on RANKL expression, fibroblasts were treated with both a small interfering RNA (siRNA) and an inhibitor of XBP1 prior to exposure to TiPs. The effect of XBP1s on osteoclasts formation was determined by tartrate-resistant acid phosphatase (TRAP) staining in vitro osteoclastogenesis assay and in animal models. The resorption of bone was assessed by micro-computed tomography (micro-CT) with three-dimensional reconstruction. Our results demonstrated that XBP1s was activated in periprosthetic membrane, mouse calvaria models, and TiPs-stimulated human synovial fibroblasts. Further, inhibition of XBP1s decreased the expression of RANKL and osteoclasts formation in vitro. In mouse calvaria models, both of the osteoclastogenesis and osteolysis were inhibited XBP1s inhibitor. Our results suggested that XBP1s mediated TiPs-induced of RANKL expression in fibroblasts, and down regulating XBP1s may represent a potential therapy for wear particle-induced osteolysis. ß
Total hip arthroplasty (THA) is commonly used in clinics to treat end-stage joint disease for its effectiveness in reducing pain and improving joint function. However, wear debris, liberated from the surface of prostheses, may result in periprosthetic osteolysis and subsequent aseptic loosening. Various wear particles play a critical role in aseptic loosening. 1 In detail, wear particles induce a chronic inflammatory response, which manifests as a granulomatous membrane at the interface of the implants and the bone that consists predominantly of fibroblasts, macrophages, and foreign body giant cells, leading to bone resorption. 2 Receptor activation of nuclear factor (NF)-kB (RANKL), a key player in supporting the differentiation and maturation of osteoclasts, can be induced directly and indirectly by wear particles in the pathological process of aseptic loosening. 3, 4 Previous studies have demonstrated that the expression of RANKL is raised in fibroblasts in the pseudomembrane surrounding failed prostheses. 5 However, the underlying mechanism of RANKL expression in fibroblasts induced by wear particles remains largely unknown. The X-box-binding protein 1 (XBP1) is a stressinducible transcription factor in the unfolded protein response (UPR) that exists in both invertebrate and vertebrate cells and is critical for cell survival under stress conditions. 6 Upon endoplasmic reticulum stress, XBP1 is spliced by Inositol-requiring enzyme-1-a (IRE1-a), thereby generating functional spliced XBP1 (XBP1s). XBP1s-dependent transcriptional reprogramming is implicated in a wide variety of pathologic and physiologic progress, including adipogenesis and lipogenesis. 7 XBP1 is required for the terminal differentiation of B lymphocytes to plasma cells. 8 In addition XBP1 is also involved in controlling the production of IL-6 in plasma cells. 9 In contrast, XBP1-deficient B cells fail to colonize the bone marrow and do not sustain antibody production. 10 Recently, our study demonstrated that IRE1-a was activated in periosteum tissue from clinical specimens. 11 However, it remains largely unknown whether XBP1s was involved in aseptic loosening. In the present study, we hypothesized that XBP1s could be involved in particle-induced osteolysis. We tested the hypothesis in interface membrane retrieved from patients with aseptic loosening, a particle-induced calvarial osteolysis model and human synovial fibroblasts.
MATERIALS AND METHODS

Particles Preparation
TiAl 6 V 4 particles (TiPs) with a mean diameter of 51.7 nm were provided by Dr. Zhenzhong Zhang (The College of Materials Science and Engineering of Nanjing University of Technology). The particles were autoclaved for 15 min at 121˚C and 15 psi for sterilization. The endotoxin level of the particles were <0.25% EU/ml as determined by a quantitative Limulus Amebocyte Lysate (LAL) Assay (Charles River, Grand Island, UK). The concentration of TiPs stock solutions was 50 mg/ml in phosphate-buffered saline (PBS). The particles were diluted in cell culture medium to attain concentrations ranging from 10 to 1,000 mg/ml and ultrasonicated for 10 min prior to exposing them to cells.
Cell Culture
Synovial fibroblasts (SFs) were harvested from surgical samples from patients with femoral neck fractures with no evidence of synovial reaction. 12 The experiment was approved by the Ethics Committee of Nanjing Jinling Hospital. Written informed consent was obtained from patients before fibroblasts were isolated. Cells were obtained by enzymatic digestion according to conventional protocols and cultured in DMEM medium supplemented with 10% FBS, penicillin (100 IU/ml) and streptomycin (100 mg/ml). Cells were maintained at 37˚C in a humidified atmosphere of 5% CO 2 and 95% air.
In Vivo Calvarial Resorption Model A wear particle-induced mouse calvarial osteolysis model was generated as previously described. 13 All animals receiving humane care according to Chinese legal requirements. All the animal work and approach have been approved by the Ethics Committee of Nanjing Jinling Hospital. Briefly, twenty-one 8-10-week-old C57BL/J6 mice were assigned randomly to three groups: Group I, shamoperated PBS mice; group II, TiPs-treated mice; and group III, TiPs co-treatment with 3-E-5, 6-D mice. Forty microliters (50 mg/ml) of the TiPs suspension was embedded under the periosteum around the middle suture of the calvaria. Group I, which received 40 ml PBS, was used as a sham control group. For groups III, 3-E-5, 6-D were injected intraperitoneally at 50 mg/kg. 3-E-5, 6-D (3-Ethoxy-5, 6-dibromosalicylaldehyde, Sigma, SML0149) was injected daily for 2 weeks until the animals were sacrificed, and the calvarial caps were removed by dissecting the bone from the underlying brain tissue.
Micro-Computed Tomography (Micro-CT) Scanning
Calvaria were scanned using a high-resolution micro-CT (SkyScan1176; SkyScan, Aartselaar, Belium) at a resolution of 18 mm and X-ray energy settings of 45 kV and 550 mA. A square region of interest (ROI) around the midline suture was selected for further qualitative and quantitative analysis after reconstruction. The bone volume/total volume (BV/TV) and percentage of total porosity of each sample were measured as reported previously.
14 Tartrate-Resistant Acid Phosphatase (TRAP) Staining Histochemical tartrate-resistant acid phosphatase (TRAP) with a commercial kit (Sigma, 387A) was performed according to the manufacturer's instructions to detect the osteoclast-like cells in bone slices. Briefly, the specimens were fixed in acetone for 2 min before being stained in 37˚C mixed solutions (acetate solution, naphthol AS-Bl phosphate solution, tartrate solution, and fast garnet GBC salt) for 1 h in the dark. Removed specimens in deionized water for 3 min and then stained in Acid Hematoxylin solution for 2 min. Rinsed the specimens in deionized water for 3 min. The presence of dark red staining granules in the bone tissue was considered as the specific criterion for TRAP positive cells. 15 The specimens were observed and photographed with a light microscope.
Tissue TRAP Activity and Elisa TRAP activity in the periosteum was determined by a commercial kit (Jiancheng Biotec, Nanjing, China). The cytokines sRANKL were quantified using enzyme-linked immunosorbent assay (ELISA) kits (BioVendor, Czech Republic). All procedures were performed according to the manufacturer's instructions.
Cell Interfering Experiment Double-strand small interfering RNA (siRNA, Invitrogen) against human XBP-1 (sense 5 0 -ACAGCAAGUGGUA-GAUUUATT-3 0 and antisense 5 0 -UAAAUCUACCACUUGCU-GUTT-3 0 ) was used in this study, and oligos without matching GeneBank sequence were used as control siRNA. The transfection procedures were as reported previously. 16 Briefly, cells were cultured in 6-well plates and transfected at 80% confluence with Lipofectamine 20,000 (Invitrogen) according to the manufacturer's instructions. The cells were left to stand for 24 h after transfection before being used for experiments.
Real-Time PCR Total RNA from cells was prepared using TRIzol reagent (Invitrogen, 15596-018) according to the manufacturer's instructions. Five micrograms total RNA was reverse transcribed to cDNA with the first-strand cDNA synthesis kit (Invitrogen, 18080-051). Real-time PCR was performed using 2Â SYBR Green qPCR Mix (Zoonbio Biotechnology Co., PC01) according to the manufacturer's protocol. Primers for GAPDH were used as internal controls. The following primers were used: RANKL, sense: 5 0 -TGGGGCTCAATCTATATCTCGAAC-3 0 and antisense: 5 0 -TGGATCACAGCACATCAGAGCAG-3 0 ; GAPDH, sense: 5 0 -ACCACAGTCCATGCCATCAC-3 0 and antisense: 5 0 -TCCACCACCCTGTTGCTGTA -3 0 .
In Vitro Osteoclastogenesis Assay As described previously, 17 primary bone marrow cells (BMMs) were isolated from the whole bone marrow with 4-week-old male C57BL/J6 mice. Briefly, BMMs were isolated from the femur bone marrow and cultured in complete a-MEM with 30 ng/ml M-CSF in a suspension culture dish at 37˚C for 2-3 days. Nonadherent cells were removed, and adherent cells were released by 0.02% EDTA in PBS. Then the cells were seeded in 24-well plates and added with medium that containing half of conditioned medium from TiPs-treated or untreated fibroblasts and half fresh medium supplemented with 15% FBS. Positive control was added with 20 ng/ml recombinant RANKL (R&D Systems, Minneapolis, MN). Cell culture media were replaced every 2 days. All groups were treated with 30 ng M-CSF (PeproTech EC Ltd., London, UK). After 8-10 days, the cells were analyzed for TRAP activity (Jiancheng, Nanjing, China): TRAP-positive cells with three or more nuclei were considered as osteoclasts and been counted under a microscope.
Specimens From Patients
Periprosthetic interface membranes were retrieved during revision operations of patients with aseptic loosening. The control specimen obtained from primary total hip replacement XBP1s MEDIATES PARTICLE-INDUCED RANKL EXPRESSION for femoral neck fracture. The experiment was approved by the Ethics Committee of Nanjing Jinling Hospital. Written informed consent was obtained from patients. The clinical data of the patients are shown in Table 1 .
Western Blotting
As previously reported, the cells, calvarial periosteum from the animals and periprosthetic interface membranes obtained from patients prepared for western blot were lysed in RIPA lysis buffer with a protein inhibitor cocktail for 30 min on ice. 11 The lysates were centrifuged at 12,000g for 10 min at 4˚C, and the supernatants were collected.
Protein concentrations were determined using a BCA protein assay kit (Biocolor Bioscience and Technology Co., Shanghai, China). Thirty micrograms of each protein were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) before being transferred to polyvinylidene fluoride membranes (Pall Co., East Hills, NY). Western blotting was performed using the following primary antibodies: Anti-RANKL (R&D system), anti-OPG (Santa Cruz) and anti-XBP1s (Santa Cruz), and the following secondary antibodies: Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and HRPconjugated anti-mouse IgG antibodies. After probing with specific primary antibodies and an appropriate secondary antibody, the protein bands were detected, and the band density was analyzed using ImageJ 1.41 (National Institutes of Health, Bethesda, MD). The whole processes from protein extracted to western blotting were performed three times.
Statistical Analysis
Results were expressed as means AE standard error of the means (SEM). The differences between groups were analyzed by BrownForsythe's test and, if appropriate, by one-way ANOVA followed by Dunnett's test or Bonferroni test. Data were analysed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). A p-value of less than 0.05 was considered significant.
RESULTS
Upregulation of XBP1s in Peri-Implant Membrane and TiPs-Treated Animals Firstly, the expression of XBP1s in periprosthetic membranes from patients with aseptic loosening was detected. We observed markedly elevated protein levels of XBP1s compared with the control tissue ( Fig. 1A and B) . Further, we examined the level of XBP1s protein in a mouse calvaria resorption model. The data showed that XBP1s protein levels were higher in the cells treated with TiPs compared to the sham group (Fig. 1C) . The expression of XBP1s induced by TiPs was threefold compared to that observed in the control (Fig. 1D) . These results demonstrated that XBP1s signaling was activated in the pathological process of wear debris-induced osteolysis both in patients and animal models.
Elevation of XBP1s in Human Synovial Fibroblasts by TiPs
Because fibroblasts consist of the primary of cells in peri-implant membrane and respond directly to wear particles, 18 we then investigated whether TiPs could stimulate the upregulation of XBP1s in human synovial fibroblasts. Figure 2A and B showed that TiPs induced XBP1s expression in fibroblasts in a dose-dependent manner. And 1,000 mg/ml TiPs was sufficient to cause an approximately threefold upregulation of XBP1s protein (Fig. 2B) . To further confirm that TiPs could increase the expression of XBP1s, we stimulated fibroblasts with various concentration of TiPs. The results showed that TiPs timedependently increased XBP1s expression ( Fig. 2C and  D) . These data demonstrated that TiPs could induced XBP1s expression in human synovial fibroblasts.
XBP1s Mediated the Upregulation of RANKL Induced by TiPs and Promoted Osteoclastogenesis in Vitro
Fibroblasts promote osteoclast formation in wear particle-induced osteolysis by producing osteoclastogenic cytokines such as RANKL. 18 So, we investigated the potential effect of XBP1s on RANKL expression in fibroblasts which stimulated by TiPs. The data indicated that both mRNA and protein levels of RANKL was elevated by TiPs in fibroblasts ( Fig. 3A and C) . As OPG is a soluble decoy receptor for RNAKL and the ratio of RANKL to OPG regulating in fine the orientation to bone formation or bone resorption, thus we further examined the ratio of RANKL/OPG. 19 The data demonstrated that the ratio of RANKL/OPG was higher in the cells treated with TiPs ( Fig. 3D-F) . We then used siRNA to decrease XBP1s expression, and the results revealed that both the expression of RANKL and the ratio of RANKL/OPG that induced by TiPs were impaired in the groups treated with siXBP1 ( Fig. 3D-F) . Treatment with siXBP1 also led to a lower level of sRANKL in cell supernatants (Fig. 3G) . To further confirm the promoting effect of XBP1s signaling on RANKL protein secretion in fibroblasts, 3-E-5, 6-D, a specific inhibitor of IRE1-a endoribonuclease that selectively inhibits Xbp1 splicing, was administered as a co-treatment with fibroblasts before adding wear particles. 20 As shown in Figure 3D -G, the RANKL protein level and the ratio of RANKL/OPG were lower in 3-E-5, 6-D plus TiPs co-treatment cells compared to that induced by TiPs alone. The compound showed no significant effect on cell viability at the dose we used (Supplementary Fig. S1 ). To investigate whether XBP1s induced by TiPs was involved in osteoclastogenesis, we examined the osteoclasts formation in vitro using BMMs. TRAP staining revealed that osteoclast formation was less in the recombinant OPG cotreated group than the TiPs group (Fig. 3H) , which suggested that the RANKL expression induced by TiPs was a driving force in osteoclastogenesis. Further, cotreatment with 3-E-5, 6-D plus TiPs group showed less osteoclast formation compared to the TiPs group (Fig. 3H) . Quantification of TARP-positive, multinucleated osteoclasts revealed that there was about twofold more osteoclasts in the TiPs group compared with that cotreated with 3-E-5, 6-D (Fig. 3I) . These results indicated that XBP1s was implicated in TiPs-induced RANKL expression and inhibition of XBP1s effectively decreased osteoclasts formation in vitro. 
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XBP1s Mediated the Upregulation of RANKL and Osteoclastogenesis in Animal Models
We examined the effect of XBP1s on RANKL expression osteoclastogenesis in a mouse calvaria osteolysis model with 3-E-5, 6-D. The data showed that the induction of XBP1s by TiPs was suppressed by cotreatment with 3-E-5, 6-D (Fig. 4A and B) . Further, treatment with 3-E-5, 6-D inhibited RANKL expression by 50% (Fig. 4B) . More importantly, the ratio of RANKL/OPG was inhibited by 3-E-5, 6-D (Fig. 4C) . Then, we explored whether the osteoclastogenesis could be alleviated by the chemical inhibitor. TRAP 
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WANG ET AL. activity in the periosteum, which indicates the activity of osteoclasts according to a TRAP quantification kit, showed that TRAP activity level was lower in 3-E-5, 6-D plus TiPs co-treatment group compared to that treated with TiPs alone (Fig. 4D) . The results obtained from histochemical staining with TRAP, which was used as a cytochemical marker for osteoclasts, were in line with the data of TRAP activity assay (Fig. 4E) . The upregulation of osteoclasts formation that induced by TiPs was inhibited by 3-E-5, 6-D (Fig. 4E ).
3-E-5, 6-D Ameliorated TiPs-Induced Osteolysis In Vivo
Micro-computed tomography (micro-CT) with threedimensional reconstruction suggested that extensive osteolysis has occurred in the TiPs group (Fig. 5A) . In the group with 3-E-5, 6-D cotreatment, wear debrisinduced bone resorption was suppressed (Fig. 5A) .
Although 3-E-5, 6-D alone had no obvious effect on the calvarial osteolysis, quantitative analysis of bone parameters confirmed that 3-E-5, 6-D plus TiPs cotreatment group had higher BV/TV level and lower percentage of total porosity relative to TiPs-treated group ( Fig. 5B and C) . Collectively, these data suggested that inhibition the expression of XBP1s could reduce TiPs-induced osteolysis in animal models.
DISCUSSION
Total hip arthroplasty is an effective surgical procedure for alleviating pain, and improving ambulation and function for patients with severe joint disease. However, the wear particles induced periprosthetic bone resorption followed by aseptic loosening remains the major cause of failed THA. Although extensive efforts have been made in bearing materials, implant technology and design, and surgical technique, these approaches are unlikely to eliminate debris generation from bearing surface. 21 Wear particles interact with multiple local cell types, such as fibroblasts, macrophages, osteoblasts, and T lymphocytes, leading to the release of various substances including TNF-a, RNAKL, IL-6, IL-1b, IL-8, and matrix metalloproteinases (MMPs). These substances lead to bone resorption and decreased bone formation. 22 Our previous study have demonstrated that ER stress contributed to the induction of proinflammatory cytokines in particle-induced osteolysis. 11 However, the downstream component of the ER stress that implicated in aseptic loosening remains largely unknown. The IRE-1/XBP-1 pathway is the most conserved branch of ER stress response pathway. IRE1a protein is a type I transmembrane protein that has both a Ser/Thr kinase domain and an endoribonuclease domain. The endoribonuclease domain processes 26 nucleotides from the XBP1mRNA. The spliced XBP1 mRNA encodes a functional XBP1s transcription factor. XBP1s is involved in a wide variety of human pathologic process. 23 In the present study, we demonstrated that XBP1s was activated in the peri-implant membrane obtained from patients. Further, in the mouse calvaria osteolysis model that treated with TiPs, the upregulation of XBP1s was also observed. These results demonstrated that XBP1s was implicated in the pathologic process of TiPs-induced osteolysis in vivo.
XBP1s has been suggested as a potential target in cancer and fibrotic disease. Blocking XBP1 splicing by inhibition of IRE-1a could be a promising therapeutic option in multiple myeloma and other cancer types. 24 In addition, XBP1 was also involved in scleroderma, an uncontrolled fibrotic disease of skin and internal organs. 25 In the present study, we showed that TiPs could increase the expression of XBP1s in fibroblasts in a dose-dependent manner. The fibroblast is the most dominant cell type in the periprosthetic membrane and responds directly to wear debris expressing proinflammatory cytokines and RANKL, and thus, be involved in osteoclastogenesis. 12 Interestingly, both siRNA of XBP1and 3-E-5, 6-D, a specific inhibitor of IRE1-a endoribonuclease that selectively inhibits Xbp1 splicing, exhibited inhibitory effects on the expression of RANKL, and the ratio of RANKL/OPG in fibroblasts induced by TiPs in vitro. Further, in animal models, the RANKL expression was also lower in 3-E-5, 6-D plus TiPs cotreatment group compared to that stimulated by TiPs alone. These data suggested that XBP1s played a key role in TiPs induced RANKL expression in vitro and in vivo.
3-E-5, 6-D (3-Ethoxy-5, 6-dibromosalicylaldehyde) is a kind of salicylaldehyde analogs, which binds directly and selectively to IRE1 to inhibit the endoribonuclease activity, with weak effects on protein kinase function. 20, [26] [27] [28] In this study, 3-E-5, 6-D decreased the expression of XBP1s that induced by TiPs in fibroblasts. There were reports described that 3-E-5, 6-D may inhibited phosphorylated Jun N-terminal kinase (JNK) and LC3-II, both of which acted downstream signaling of RANKL during osteoclast formation. [29] [30] [31] [32] [33] [34] [35] Although we have not detected the effect of 3-E-5, 6-D on JNK and LC3-II in the present study, our data demonstrated that 3-E-5, 6-D decreased TiPs-induced RANKL expression by inhibiting XBP1s and treatment with 3-E-5, 6-D was sufficient to decreased osteoclast formation by inhibiting the expression of RANKL. These results suggested that the inhibitory effect of 3-E-5, 6-D on XBP1s and the subsequently RANKL expression was the main effect in the present experimental model.
While the results discussed above suggested a key role of XBP1s in the expression of RANKL and osteoclastogenesis, we further investigated whether XBP1s could be a potential target in TiPs-induced osteolysis. We found that inhibition of XBP1s by 3-E-5, 6-D alleviated bone resorption induced by TiPs in vivo. These results indicated that blockade of XBP1s could represent a potential therapy for wear particles-induced osteolysis.
Collectively, our results demonstrated for the first time that XBP1s mediated TiPs-induced of RANKL expression in fibroblasts. Further, both the RANKL expression and osteoclasts formation induced by TiPs were attenuated by inhibition of XBP1s in vitro and in an animal model of particle-induced osteolysis. Inhibition of XBP1s led in amelioration of osteolysis induced by the implanted particles. Our findings suggested a possible mechanism underling the RANKL expression induced by TiPs in fibroblasts and down regulating XBP1s may represent a potential therapy for wear particle-induced osteolysis.
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